657 related articles for article (PubMed ID: 25810549)
1. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
2. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
3. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway.
Gatto G; Rossi A; Rossi D; Kroening S; Bonatti S; Mallardo M
Nucleic Acids Res; 2008 Nov; 36(20):6608-19. PubMed ID: 18940871
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Martin KA; Lupey LN; Tempera I
J Virol; 2016 Oct; 90(19):8520-30. PubMed ID: 27440880
[TBL] [Abstract][Full Text] [Related]
7. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
8. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway.
Wang L; Howell MEA; Sparks-Wallace A; Zhao J; Hensley CR; Nicksic CA; Horne SR; Mohr KB; Moorman JP; Yao ZQ; Ning S
mBio; 2021 Oct; 12(5):e0109721. PubMed ID: 34488443
[TBL] [Abstract][Full Text] [Related]
9. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.
Goormachtigh G; Ouk TS; Mougel A; Tranchand-Bunel D; Masy E; Le Clorennec C; Feuillard J; Bornkamm GW; Auriault C; Manet E; Fafeur V; Adriaenssens E; Coll J
J Virol; 2006 Aug; 80(15):7382-93. PubMed ID: 16840319
[TBL] [Abstract][Full Text] [Related]
10. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
[TBL] [Abstract][Full Text] [Related]
11. Latent membrane protein 1 of Epstein-Barr virus regulates death-associated protein kinase 1 in lymphoblastoid cell line.
Lee CW; Leu SJ; Tzeng RY; Wang SF; Tsai SC; Sun KH; Chen RH; Huang JC
Virology; 2011 Apr; 413(1):19-25. PubMed ID: 21353277
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.
Price AM; Tourigny JP; Forte E; Salinas RE; Dave SS; Luftig MA
J Virol; 2012 Oct; 86(20):11096-106. PubMed ID: 22855490
[TBL] [Abstract][Full Text] [Related]
13. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
14. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
[TBL] [Abstract][Full Text] [Related]
15. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
16. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
17. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.
Konforte D; Simard N; Paige CJ
Virology; 2008 Apr; 374(1):100-13. PubMed ID: 18222514
[TBL] [Abstract][Full Text] [Related]
19. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
20. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
